Quanterix Stock Price, News & Analysis

Quanterix Corporation (NASDAQ: QTRX) has appointed Karen A. Flynn, Chief Commercial Officer of Catalent Pharma Solutions (NYSE: CTLT), to its Board of Directors effective June 6, 2022. With over 35 years in the pharmaceutical services industry, Flynn's experience includes leadership roles at Catalent and West Pharmaceutical Services. Her expertise in commercial strategy and operations is expected to drive Quanterix's growth and enhance its impact in healthcare research and diagnostics.

Quanterix (NASDAQ: QTRX) announced a 9% year-over-year revenue growth for Q1 2022, totaling $29.6M, driven by a 13% increase in product revenue. However, the company's gross margin dropped to 49.3% from 60.1% in the prior year, prompting a reevaluation of inventory management. Significant business milestones include new agreements with Lilly for Alzheimer's diagnostics, funding from the Alzheimer's Drug Discovery Foundation, and notable academic publications utilizing Quanterix's Simoa technology.

Quanterix Corporation (NASDAQ: QTRX) will release its Q1 2022 financial results on May 10, 2022, before trading begins. The management team, including President & CEO Masoud Toloue and CFO Michael Doyle, will discuss the results in a conference call at 8:30 a.m. EST. Interested listeners can join the call via phone or a live webcast. Quanterix specializes in digitizing biomarker analysis to enhance precision health through its Simoa technology, supporting research across various therapeutic areas.

Quanterix Corporation (NASDAQ: QTRX) announced that its Simoa® neurofilament light chain (NfL) plasma test received FDA Breakthrough Device designation for assessing disease activity in relapsing-remitting multiple sclerosis (RRMS) patients. This designation supports accelerated development and regulatory review for technologies that address significant medical needs. The NfL test quantitatively measures NfL in blood, aiding in identifying RRMS patients' relapse risks. This marks the second Breakthrough Device designation for Quanterix, following the phospho-Tau 181 test for Alzheimer’s disease.

Quanterix Corporation (NASDAQ: QTRX) has announced a significant advancement in multiple sclerosis (MS) management through its Simoa® technology. A comprehensive study published in The Lancet Neurology established reference ranges for the serum neurofilament light chain (sNfL) biomarker, aiding in disease assessment at the individual level. The study analyzed over 20,000 samples, creating a robust database for clinical interpretation. This development hopes to enhance personalized treatment decisions for MS patients.

Quanterix Corporation (NASDAQ: QTRX) has partnered with the Alzheimer’s Drug Discovery Foundation (ADDF) to enhance the development of a multi-analyte plasma test for early Alzheimer's disease detection. Funded clinical trials will be conducted in collaboration with Amsterdam University Medical Centers, led by Professor Charlotte Teunissen. The initiative aims to provide accessible diagnostics to link patients with new therapies. The ADDF has financed over $209 million for Alzheimer's drug development since its inception.

Quanterix Corporation (NASDAQ: QTRX) will have its Chairman and CEO, Kevin Hrusovsky, present at the Barclays Global Healthcare Conference on March 15, 2022, at 10:45 a.m. EST. Attendees can register for virtual participation. Hrusovsky will also conduct one-on-one meetings with institutional investors on the same day. A live webcast of his presentation will be available on the Quanterix investor relations website, with replays accessible for 90 days. Quanterix specializes in digitizing biomarker analysis to enhance precision health.

Quanterix Corporation (NASDAQ: QTRX) has announced that its Chairman and CEO, Kevin Hrusovsky, will present at The Cowen 42nd Annual Health Care Conference on March 9, 2022, at 9:50 a.m. EST. Investors can register for a live webcast at the Quanterix investor relations page. Additionally, Hrusovsky will hold virtual meetings with institutional investors on March 8 and 9. Quanterix aims to advance precision health through its Simoa technology to enable early disease detection and better treatment methods.

Quanterix Corporation has entered a collaboration with Eli Lilly to enhance the diagnosis and treatment of Alzheimer’s disease. This partnership includes a non-exclusive license to Lilly’s P-tau217 antibody technology and a commitment of $11 million from Lilly for development this year. The collaboration aims to develop blood-based biomarkers, which could simplify and improve Alzheimer’s diagnostics and treatment monitoring, potentially reducing reliance on invasive procedures. The initiative puts Quanterix in a strong position in Alzheimer’s research and diagnostics.